Fresenius/€FRE
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Fresenius
Fresenius SE & Co. KGaA, operating under the ticker FRE, is a global healthcare group founded in 1912. The company specializes in products and services for dialysis, hospitals, and outpatient medical care. Operating in the healthcare sector, Fresenius provides a range of services including engineering and services for hospitals and other healthcare facilities.
Ticker
€FRE
Sector
Primary listing
XETRA
Employees
176,207
Headquarters
Website
Fresenius Metrics
BasicAdvanced
€28B
25.00
€2.00
1.01
€1.00
2.00%
Price and volume
Market cap
€28B
Beta
1.01
52-week high
€50.74
52-week low
€31.60
Average daily volume
42K
Dividend rate
€1.00
Financial strength
Current ratio
1.312
Quick ratio
0.637
Long term debt to equity
55.939
Total debt to equity
67.849
Dividend payout ratio (TTM)
58.31%
Interest coverage (TTM)
3.79%
Profitability
EBITDA (TTM)
2,610
Gross margin (TTM)
24.28%
Net profit margin (TTM)
5.05%
Operating margin (TTM)
8.41%
Effective tax rate (TTM)
28.97%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
5.83%
Valuation
Price to earnings (TTM)
24.998
Price to revenue (TTM)
1.263
Price to book
1.54
Price to tangible book (TTM)
19.38
Price to free cash flow (TTM)
22.753
Free cash flow yield (TTM)
4.40%
Free cash flow per share (TTM)
2.194
Dividend yield (TTM)
2.00%
Forward dividend yield
2.00%
Growth
Revenue change (TTM)
4.32%
Earnings per share change (TTM)
-200.90%
3-year revenue growth (CAGR)
-9.21%
10-year revenue growth (CAGR)
-1.51%
3-year earnings per share growth (CAGR)
-11.55%
10-year earnings per share growth (CAGR)
-0.73%
3-year dividend per share growth (CAGR)
2.82%
10-year dividend per share growth (CAGR)
8.56%
What the Analysts think about Fresenius
Analyst ratings (Buy, Hold, Sell) for Fresenius stock.
Bulls say / Bears say
Fresenius has increased its 2025 organic revenue growth target to 5–7% from 4–6% and delivered Q2 EBIT excluding special items of €654 million, 2.6% above analysts’ expectations, highlighting strong first-half results (Reuters).
In Q1 2025, Fresenius achieved €654 million in EBIT before special items, above the €634 million consensus, driven by strong performance at Fresenius Kabi, while reaffirming its 2025 guidance for 4–6% revenue and 3–7% EBIT growth at constant currency (Reuters).
The planned reduction of its FMC stake to around 28.6% will provide funds to invest in higher-margin areas such as Fresenius Kabi and its Helios hospital network, in line with the #FutureFresenius strategy, sharpening the company’s strategic focus and growth prospects (Reuters).
Fresenius’s remaining approximately 28.6% stake in Fresenius Medical Care remains subject to FMC’s business volatility—a risk exemplified by flat same-market treatment volumes and a Q2 earnings miss caused by a severe U.S. flu season, which may limit parent company returns (Reuters).
Fresenius’s need to sell FMC shares pro rata in order to maintain its stake after the buyback suggests reliance on asset disposals rather than organic cash flow, raising questions about underlying operating cash generation (Reuters).
The nearly 12% strengthening of the euro against the U.S. dollar in H1 2025 likely produced a mid-single-digit percentage headwind on Fresenius’s revenues denominated in dollars, putting pressure on its reported top-line growth (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2025.
Fresenius Financial Performance
Revenues and expenses
Fresenius Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fresenius stock?
Fresenius (FRE) has a market cap of €28B as of November 03, 2025.
What is the P/E ratio for Fresenius stock?
The price to earnings (P/E) ratio for Fresenius (FRE) stock is 25 as of November 03, 2025.
Does Fresenius stock pay dividends?
Yes, the Fresenius (FRE) stock pays dividends to shareholders. As of November 03, 2025, the dividend rate is €1 and the yield is 2%. Fresenius has a payout ratio of 58.31% on a trailing twelve-month basis.
When is the next Fresenius dividend payment date?
The next Fresenius (FRE) dividend payment date is unconfirmed.
What is the beta indicator for Fresenius?
Fresenius (FRE) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.